Читать книгу Transfusion Medicine - Jeffrey McCullough - Страница 180

Lymphocytes or monocytes are being used increasingly as starting material for the production of cells for adoptive immunotherapy, genetically engineered immunotherapy like chimeric antigen receptor (CAR) T‐cell therapy, or as a concentrate enriched in PBSCs (see Chapter 19). With the exception of donor lymphocyte infusion in the setting of transplant, lymphocytapheresis is almost always performed on patients. Thus, there are no established criteria for normal donor selection and management; however, yields of 1–3 × 10¹⁰ MNCs are typical.